Creative Enzymes Launches AI-Integrated Biocatalysis Platform to Accelerate Enzyme Development

Creative Enzymes, a global enzyme technology service provider, has launched an AI-integrated biocatalysis platform designed to accelerate enzyme development and address the growing demand for efficient biomanufacturing. The platform merges computational enzyme engineering with hands-on process development, delivering AI-Driven Biocatalysis Solutions that are both predictable in silico and practical at industrial scale. Traditional enzyme development often struggles to keep pace with iterative product development, but AI brings critical value by predicting enzyme candidates, designing enzymes constrained by process parameters, and leveraging molecular features to anticipate performance.

The benefits extend beyond speed. AI techniques reduce the need to test myriad biocatalyst variants, saving R&D costs and lowering the risk of process failure by identifying suitable biocatalysts early in development. The platform also opens routes to molecules previously inaccessible to enzymatic conversion, enabling new product opportunities. Its capabilities are delivered through three service modules: AI-Driven Biocatalyst Discovery & Engineering, AI-Driven Industrial Biocatalysis, and AI-Driven Green Biocatalysis.

The discovery and engineering module provides an end-to-end workflow from target reaction analysis to scale-up characterization, encompassing computational screening, process optimization, and scale-up evaluation. For moderately complex targets, this reduces the design-build-test-learn cycle from 12-24 months to 8-12 months. The industrial biocatalysis module addresses the journey from reaction engineering to full-scale implementation, including substrate concentration optimization, cofactor regeneration, immobilization, and integration of process analytical technology. The green biocatalysis module focuses on sustainability, leveraging enzymatic reactions in aqueous media at room temperature to minimize organic solvents, energy consumption, and byproduct formation.

The platform's capabilities were demonstrated in a recent case study on transaminase engineering. Researchers developed a 6D protein engineering framework combining interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations. Five AI-selected transaminase variants, each with nine mutations, exhibited high solubility and catalytic stability at 7-liter fermentation scale. The engineered enzymes converted prochiral ketones to sitagliptin, achieving enantiomeric purity exceeding 99% and conversion rates of up to 89% during scale-up.

AI biocatalysis is making significant inroads in pharmaceuticals, particularly for asymmetric synthesis of chiral intermediates and replacing hazardous reagents. Agrochemicals and food industries are also adopting the technology to fine-tune toxicology profiles and deliver cleaner labels through enzymatic modification. Fine chemicals and personal care sectors are exploring high-value conversions and milder, more sustainable processes.